To create and commercialize innovative blood tests that accurately assess imminent disease risk, enabling healthcare providers to preempt the onset of chronic cardiometabolic conditions by focusing healthcare resources on those patients who will benefit the most from early and aggressive intervention.
Tethys was established in 2005 with a singular focus: to reduce the clinical and economic burden of preventable, chronic diseases by preempting their development. Recognizing the urgent need for better ways to address one of the most debilitating and economically devastating preventable diseases in the world, the company’s founders first turned their attention to type 2 diabetes, pursuing the development of a novel approach designed to transform the way diabetes and other cardiometabolic diseases are assessed and treated. In June 2008, less than three years after its founding, Tethys proudly unveiled its first product, the PreDx® Diabetes Risk Score (PreDx® DRS).
Tethys markets PreDx DRS directly to primary care physicians who have been overwhelmed by a vast, poorly-differentiated “at risk” population that cannot be efficiently managed. The enhanced risk stratification offered by the PreDx DRS now empowers these physicians to focus interventions on their highest-risk patients, creating a tangible opportunity to disrupt disease progression and preempt disease onset.
Today, Tethys continues to build a sustainable cardiometabolic diagnostics business by expanding its commercial infrastructure and establishing partnerships to increase physician use.
The Tethys development pipeline includes products to determine risk for first-time heart attack, osteoporotic fracture and other cardiometabolic diseases, and is also working on tests that can be used to determine the quality of diet and exercise programs. At Tethys, a force of dedicated employees works together to ensure that physicians have access to these valuable risk stratification tools - tools that can help physicians better serve their patients and dramatically increase the scope and impact of their disease prevention efforts.
In late 2009, Tethys received the BayBio Fast Start Award at the Northern California Life Science Group’s annual meeting. The company was recognized for its speed of product development and its progress toward broad commercialization of its first product, the PreDx® Diabetes Risk Score.